UBS O'Connor’s Heron Therapeutics HRTX Stock Holding History

UBS O'Connor’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200,000	Closed	-$495K	–	274
2019 Q1	$495K	Buy	+200,000	New	+$5.24M	0.01%	203

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS O'Connor's HRTX Position: Q3 2022 in Review

UBS O'Connor sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 10,145,000 shares — an estimated $28.3M sold.

UBS O'Connor first reported a position in HRTX in Q1 2019 and held it in 12 quarters. The position peaked at $75.6M in Q4 2021. 185 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

UBS O'Connor reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 10,145,000 Heron Therapeutics shares in Q3 2022, an estimated $28.3M.
UBS O'Connor first reported a position in Heron Therapeutics in Q1 2019 and held it in 12 quarters.
UBS O'Connor's Heron Therapeutics position peaked at $75.6M in Q4 2021.
185 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.